Abstract
Background: Aicardi-Goutières syndrome 6 (AGS6) is a serious autoimmunization-associated acute neurologic decompensation. AGS6 manifests as acute onset of severe generalized dystonia of limbs and developmental regression secondary to febrile illness mostly. Dyschromatosis symmetrica hereditaria (DSH), as pigmentary genodermatosis, is characterized by a mixture of hyperpigmented and hypopigmented macules. Both AGS6 and DSH are associated with ADAR1 pathogenic variants.
Methods: To explore the etiology of a proband with developmental regression and a mixture of hyperpigmentation and hypopigmentation macules, we used trio-whole exome sequencing (WES). Later, to clarify the association between variants and diseases, we used guidelines of ACMG for variants interpretation and quantitative Real-time PCR for verifying elevated expression levels of interferon-stimulated genes.
Results: By WES, we detected two variants in ADAR1 and one variant in TSC2: NM_001111.5: c.1096_1097del, NM_001111.5: c.518A>G, and NM_000548.5: c.1864C>T, respectively. Variant interpretation suggested that these three variants were pathogenic. Expression levels of interferon-stimulated genes also elevated as expected.
Conclusion: We verified the co-occurrence of pathogenic variants of ADAR1 and TSC2 in AGS6 patients with DSH. Our work contributes to the elucidation of the ADAR1 pathogenic mechanism; given the specific pathogenic mechanism of ADAR1, it is necessary to consider with caution when variants are found in this gene.
Introduction
In medical genetics, clinicians often search for a single "smoking gun"—one gene variant that explains a patient's entire clinical picture. However, as genomic testing becomes more comprehensive, we are discovering cases of "blended phenotypes" where multiple independent genetic conditions coexist. This paper details a rare clinical case where a pediatric patient presented with a "dual diagnosis" of Aicardi-Goutières syndrome 6 (AGS6) and Tuberous Sclerosis Complex (TSC).
This study focuses on the diagnostic challenges surrounding ADAR1, a gene responsible for sensing viral-like RNA. Mutations in ADAR1 can cause two distinct diseases: AGS6, a severe inflammatory brain disease, and Dyschromatosis symmetrica hereditaria (DSH), a skin pigment disorder. The authors investigate a 15-month-old girl with severe neurological regression and skin abnormalities to determine how variants in ADAR1 and a second gene, TSC2 (linked to Tuberous Sclerosis), interact to produce her complex symptoms.
Methods
The researchers used a combination of genomic and functional assays to characterize the patient's condition:
- Trio-Whole Exome Sequencing (WES): Sequencing the DNA of the child (proband) and both parents to identify inherited and de novo variants.
- ACMG/AMP Variant Interpretation: Applying the standard clinical framework to classify the pathogenicity of the discovered variants (e.g., Pathogenic vs. Likely Pathogenic).
- RT-qPCR (Interferon Signature): Measuring the expression levels of five Interferon-Stimulated Genes (ISGs: IFIT1, IFI27, ISG15, IFI44L, RSAD2). Elevated ISGs serve as a functional biomarker for type I interferonopathies like AGS6.
- In Silico Analysis: Using computational tools and amino acid sequence alignment across species to predict how the mutations affect protein conservation and function.
The primary dataset consisted of genomic and transcriptomic data from the proband and her parents. To validate the interferon signature, the authors used peripheral blood samples from three healthy, age-matched children as a control group. Reference data for variant filtering and frequency were pulled from standard public databases including GnomAD, ClinVar, HGMD, and 1000 Genomes.
Results
The 15-month-old proband exhibited developmental regression, basal ganglia calcification (confirmed via CT), and a mixture of hyper- and hypopigmented skin macules. Genomic analysis identified three significant variants: two in ADAR1 and one in TSC2.
The patient was a compound heterozygote for ADAR1, inheriting a frameshift mutation (c.1096_1097del) from her father and a missense mutation (c.518A>G) from her mother. While the father only showed skin spots (DSH), the combination in the daughter led to severe AGS6. Surprisingly, the patient also inherited a pathogenic TSC2 variant (c.1864C>T) from her father. While the severe neurological symptoms of AGS6 dominated the clinical presentation, the TSC2 variant puts the patient at risk for Tuberous Sclerosis, which typically involves benign tumor growth in multiple organs.
Functional validation via RT-qPCR revealed that all five tested ISGs were significantly upregulated in the proband compared to healthy controls, confirming the diagnosis of a type I interferonopathy. Furthermore, sequence alignment showed that the variants occurred at highly conserved residues across species, from humans to rats, reinforcing their functional importance.
Discussion and Conclusion
This case highlights the importance of isoform specificity in ADAR1. The gene produces two protein isoforms: p110 and p150. The p150 isoform is specifically induced by interferon. Mutations that reduce p150 expression often lead to the DSH skin phenotype, whereas mutations in the Zα region (like the c.518A>G found here) are critical for the development of AGS6.
Even though the patient was already receiving treatment, her "interferon signature" remained significantly elevated, proving that ISG quantification is a robust diagnostic tool for this class of diseases. However, as a single case study, it is difficult to determine if there is a synergistic biological interaction between the mTOR pathway (affected by TSC2) and the interferon pathway (affected by ADAR1) or if the phenotypes are simply additive.
In conclusion, the co-occurrence of pathogenic variants in ADAR1 and TSC2 underscores the necessity of a multi-dimensional diagnostic approach. Given the specific pathogenic mechanisms of ADAR1, clinicians must exercise caution when variants are found in this gene, as the clinical outcome can be highly variable and complicated by co-existing genetic conditions.
Summary updated